Next-Generation Sequencing (NGS) Market: Industry Outlook by Offering (Sample Preparation [DNA Extraction, Library Preparation, Automation], Systems, Bioinformatics, Sequencing Services) Application (Clinical, Research) End User — Global Forecast to 2031

Next-Generation Sequencing (NGS) Market: Industry Outlook by Offering (Sample Preparation [DNA Extraction, Library Preparation, Automation], Systems, Bioinformatics, Sequencing Services) Application (Clinical, Research) End User—Global Forecast to 2031

The global next-generation sequencing (NGS) market is projected to reach $42.7 billion by 2031 at a CAGR of 15.7% from 2024 to 2031.

Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities.

The growth of the NGS market is driven by the rising cancer prevalence & the increasing application of NGS in cancer treatment and research, partnerships between NGS service providers & pharmaceutical companies, technological advancements in NGS, the growing demand for optimized & streamlined NGS workflows, the declining costs of genome sequencing, technological advancements in sequencing procedures, technological advancements in NGS informatics solutions, increasing pharmaceutical R&D expenditures, the surge in genome mapping programs, and improvements in regulatory & reimbursement scenarios for NGS-based diagnostic tests.

Furthermore, the increasing applications of NGS, the rising adoption of bioinformatics and genomic data management solutions, collaborations between vendors to develop library preparation protocols, the growing use of bioinformatics and genomic data management solutions for large-scale data analysis and interpretation, the increasing adoption of NGS informatics tools among hospitals and clinical laboratories, and government initiatives supporting large-scale genomic sequencing projects are expected to generate growth opportunities for the players operating in the NGS market.

The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over four years (2021–2024). The key players operating in the global next-generation sequencing (NGS) market are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Revvity, Inc. (U.S.), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), Pacific Biosciences of California, Inc. (U.S.), Danaher Corporation (U.S.), Oxford Nanopore Technologies Plc. (U.K.), MGI Tech Co., Ltd. (China), Tecan Group Ltd. (Switzerland), Beijing Genomics Institute (BGI) (China), Eppendorf AG (Germany), Hamilton Company (U.S.), Hudson Robotics (U.S.), LGC Limited (U.K.), Fabric Genomics, Inc. (U.S.), DNASTAR, Inc. (U.S.), Eurofins Scientific SE (Luxembourg), Novogene Co. Ltd. (China), and Quest Diagnostics Incorporated (U.S.).

Among the offerings studied in this report, in 2024, the commercial sequencing/outsourced services segment is expected to account for the largest share of 38.0% of the market. The large market share of this segment can be attributed to the benefits offered by NGS service providers, including quick results, cost-effectiveness, and a wide array of services available for various applications.

Among the applications studied in this report, in 2024, the research & other applications segment is expected to account for the largest share of 62.2% of the next-generation sequencing (NGS) market. The large share of the segment is attributed to the decreasing cost of sequencing procedures, increasing R&D by pharmaceutical and biotechnology companies for drug discovery, the increasing applications of NGS in multiple clinical and research settings, and the increasing use of informatics solutions to find pharmacological targets, confirm therapeutic hypotheses, and predict the potential safety of inhibitory compounds aimed at molecular targets.

Among the end users studied in this report, in 2024, the pharmaceutical & biotechnology companies segment is expected to account for the largest share of 43.5% of the next-generation sequencing (NGS) market. The large market share of this segment can be attributed to the increasing R&D spending by pharmaceutical & biotechnology companies and the rising incidence of chronic diseases, which drive the adoption of next-generation sequencing products among pharmaceutical & biotechnology companies.

An in-depth analysis of the geographical scenario of the global next-generation sequencing (NGS) market provides detailed qualitative and quantitative insights into five major regions (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2024, North America is expected to account for the largest share of over 48.7% of the next-generation sequencing (NGS) market. Additionally, in 2024, the U.S. is expected to account for the largest share of the next-generation sequencing (NGS) market in North America. North America’s large market share is attributed to the favorable government initiatives for genomic research, growing applications of sequencing-based research, presence of leading providers of next-generation sequencing technologies in the region, increasing research investments by pharmaceutical and biopharmaceutical companies, declining cost of sequencing coupled with the rising availability of advanced sequencing products and solutions, increasing cancer prevalence, and favorable reimbursement scenario in the region.

Scope of the Report:

Next-Generation Sequencing (NGS) Market Assessment—by Offering

Sample Preparation
Kits & Reagents
Nucleic Acid Extraction and Amplification
Library Preparation
DNA Library Preparation
RNA Library Preparation
Quality Control
Other Reagents (1)
Workstations/Robotic Platforms for Library Preparation
Sequencing
NGS Systems
Sequencing by Synthesis
Ion Semiconductor Sequencing
Single-molecule Real-time Sequencing (SMRT)
DNA Nanoball (DNB) Sequencing
Other Technologies (2)
Services (3)
Data Analysis/Bioinformatics
Software
By Type
Data Analysis Software
Data Interpretation and Reporting Tools
Data Storage and Computing Tools
Laboratory Information Management Systems (LIMS)
By Deployment Mode
Web and Cloud-based
On-premise
NGS Informatics Services (4)
Commercial Sequencing/ Outsourced Services
Targeted Sequencing Services
RNA Sequencing Services
Whole Genome Sequencing Services
De Novo Sequencing Services
Exome Sequencing Services
ChIP Sequencing Services
Methyl Sequencing Services
Other Commercial Sequencing Services (5)

Next-Generation Sequencing (NGS) Market Assessment—by Application

Research & Other Applications
Drug Discovery
Agriculture & Animal Research
Other Applications (6)
Clinical Applications
Reproductive Health Diagnosis
Oncology
Infectious Diseases
Other Clinical Applications (7)

Next-Generation Sequencing (NGS) Market Assessment—by End User

Hospitals & Diagnostic Laboratories
Pharmaceutical & Biotechnology Companies
Academic Institutes & Research Centers
Other End Users (8)

Note: 1. Other Reagents include dilution buffers, DNA standards, target enrichment kits/reagents, and other reagents required to support the NGS sample preparation workflow
2. Other Technologies include Nanopore sequencing & Avidity Sequencing Technology
3. Services include support services, such as the upgradation of software, customer support, equipment training, monitoring, installation services, and more
4. NGS informatics services include support services, such as bioinformatics data analysis services, bioinformatics consulting services, bioinformatics training, and IT professional services.
5. Other Commercial Sequencing Services include degradome sequencing, ribosome profiling, amplicon sequencing, CRISPR validation, viral genome sequencing, and immunogenomics services
6. Other Applications include food microbiology, microbiota analysis in the beverage industry, and environmental studies
7. Other Clinical Applications include detection of genetic aberrations in neurological disorders, rare diseases, metabolic and immune disorders, and food-borne illnesses
8. Other End Users include forensic laboratories & security agencies, food & beverage companies, and agriculture companies.

Next-Generation Sequencing (NGS) Market Assessment—by Geography

North America
U.S.
Canada
Europe
Germany
France
Italy
U.K.
Spain
Rest of Europe (RoE)
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific (RoAPAC)
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa

Next-Generation Sequencing (NGS) Market: Industry Outlook

Report Metrics	Details
Years Considered	2022 - 2031
Base Year	2023
Forecast Period	2024-2031
Page Count	451
Units Referenced	Value (USD Million)
Segments/Key Topics	Market by Offering, Application, End User, and Geography
Regions Covered	North America, Europe, Asia–Pacific, Latin America, and the Middle East & Africa
Key Companies Mentioned	Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Revvity, Inc. (U.S.), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), Pacific Biosciences of California, Inc. (U.S.), Danaher Corporation (U.S.), Oxford Nanopore Technologies Plc. (U.K.), MGI Tech Co., Ltd. (China), Tecan Group Ltd. (Switzerland), Beijing Genomics Institute (BGI) (China), Eppendorf AG (Germany), Hamilton Company (U.S.), Hudson Robotics (U.S.), LGC Limited (U.K.), Fabric Genomics, Inc. (U.S.), DNASTAR, Inc. (U.S.), Eurofins Scientific SE (Luxembourg), Novogene Co. Ltd. (China), and Quest Diagnostics Incorporated (U.S.)

FAQs About the Report

What is the focus of the NGS market study?

The global NGS market report covers the qualitative analysis and sizing of the market based on offering, application, and end user. It provides an analysis of these market segments at the regional and country level. The report also provides insights on factors impacting market growth, regulatory analysis, pricing analysis, and Porter’s five forces analysis.

What is the revenue generated from the sales of NGS solutions across the globe?

The global NGS market is projected to reach $42.7 billion by 2031 at a CAGR of 15.7% from 2024 to 2031.

Which offering segment is estimated to hold the major share of the market in 2024?

Among all the offerings studied in this report, in 2024, the commercial sequencing/outsourced services segment is expected to account for the largest share of the NGS market. The large market share of this segment can be attributed to the advantages offered by commercial sequencing/outsourced services, such as rapid delivery of results, access to advanced instruments and trained professionals, and lower costs compared to in-house sequencing.

Which application segment is estimated to hold the major share of the market in 2024?

Among all the applications studied in this report, in 2024, the research & other applications segment is expected to account for the largest share of the NGS market. The large share of the segment is attributed to the decreasing cost of sequencing procedures, increasing R&D by pharmaceutical and biotechnology companies for drug discovery, the increasing applications of NGS in multiple clinical and research settings, and the increasing use of informatics solutions to find pharmacological targets, confirm therapeutic hypotheses, and predict the potential safety of inhibitory compounds aimed at molecular targets.

What are the key factors supporting the growth of this market? Also, what are the major opportunities for existing market players and new entrants in the global NGS market?

The growth of the NGS market is driven by the rising cancer prevalence & the increasing application of NGS in cancer treatment and research, partnerships between NGS service providers & pharmaceutical companies, technological advancements in NGS, the growing demand for optimized & streamlined NGS workflows, the declining costs of genome sequencing, technological advancements in sequencing procedures, technological advancements in NGS informatics solutions, increasing pharmaceutical R&D expenditures, the surge in genome mapping programs, and improvements in regulatory & reimbursement scenarios for NGS-based diagnostic tests.

Furthermore, the increasing applications of NGS, the rising adoption of bioinformatics and genomic data management solutions, collaborations between vendors to develop library preparation protocols, the growing use of bioinformatics and genomic data management solutions for large-scale data analysis and interpretation, the increasing adoption of NGS informatics tools among hospitals and clinical laboratories, and government initiatives supporting large-scale genomic sequencing projects are expected to generate growth opportunities for the players operating in the NGS market.

Who are the major players operating in the global NGS market?

The key players operating in the global NGS market are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Revvity, Inc. (U.S.), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), Pacific Biosciences of California, Inc. (U.S.), Danaher Corporation (U.S.), Oxford Nanopore Technologies Plc. (U.K.), MGI Tech Co., Ltd. (China), Tecan Group Ltd. (Switzerland), Beijing Genomics Institute (BGI) (China), Eppendorf AG (Germany), Hamilton Company (U.S.), Hudson Robotics (U.S.), LGC Limited (U.K.), Fabric Genomics, Inc. (U.S.), DNASTAR, Inc. (U.S.), Eurofins Scientific SE (Luxembourg), Novogene Co. Ltd. (China), and Quest Diagnostics Incorporated (U.S.).

Which regions/countries are likely to offer significant growth opportunities for the vendors in this market during the analysis period?

Countries like China and India within Asia-Pacific are poised to offer significant growth opportunities for the vendors in this market. The growth of this regional market is driven by rapid economic growth across many countries, resulting in increased government focus on healthcare improvement. This has led to substantial investments in enhancing healthcare service accessibility, upgrading infrastructure, and fostering drug discovery and genome mapping initiatives.